BioCentury
ARTICLE | Clinical News

3-V reports Phase I data for NASH candidate

October 27, 2017 6:50 PM UTC

3-V Biosciences Inc. (Menlo Park, Calif.) reported data from a Phase I trial in 20 healthy volunteers with a BMI of >26 and characteristics of metabolic syndrome showing that a once-daily 50 mg dose of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) candidate TVB-2640 reduced mean hepatic de novo lipogenesis (DNL), the primary endpoint, by 24% compared to baseline. The oral fatty acid synthase (FASN; FAS) inhibitor was generally well tolerated...

BCIQ Company Profiles

Sagimet Biosciences Inc.